Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
1
What Happened
Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved u...
2
Why It Matters
Akeso’s expanded trial data positions ivonescimab to capture a significant share of the $20B NSCLC market, challenging established PD-1 inhibitors.
3
Who's Affected
Akeso